Jun 2026 (Q2 FY26) — Jul 29, 2026
Integra LifeSciences Q2 FY26 — Strong Operational Execution and Reaffirmed Full-Year Outlook
Read the full callIntegra LifeSciences (IART) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Integra LifeSciences earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 419 | +0.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 4.6 | +128.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 4.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$13.45 +1.82% · +$0.24
Performance −10.8% 1Y
1Y: $15.08 on 17 Oct 2025 → $13.45. High $19.85 (16 Jul 2026), low $8.9 (18 Mar 2026).
- Previous close
- $13.21
- 52-week range
- $8.9 – $19.85
- One year
- −14.28%
Overview
- Symbol
- IART
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Integra LifeSciences earnings calls (IART)
Financials
What the filings say
Net profit, year on year: +101% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 381 | 443 | 383 | 416 | 402 | 435 | 392 | 419 |
| Expenses | 389 | 407 | 398 | 928 | 390 | 412 | 380 | 399 |
| Operating profit | -8 | 36 | -15 | -513 | 12 | 23 | 11 | 19 |
| Operating margin | −2.1% | 8.1% | −4.0% | −123.4% | 2.9% | 5.3% | 2.9% | 4.6% |
| Interest | 19 | 19 | 19 | 21 | 23 | 24 | 22 | 23 |
| Profit before tax | -20 | 23 | -30 | -531 | -7 | 4 | -2 | 5 |
| Tax rate | 47.5% | 13.8% | 15.8% | 8.8% | 20.8% | 139.5% | −91.7% | 5.5% |
| Net profit | -11 | 19 | -25 | -484 | -5 | -2 | -5 | 4 |
| EPS ($ per share) | -0.14 | — | -0.33 | -6.31 | -0.07 | — | -0.06 | 0.06 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | 348 | 399 | 532 | 699 | 879 | 947 | 940 | 423 |
| Total liabilities | 1,732 | 1,887 | 2,100 | 2,098 | 2,085 | 2,194 | 2,492 | 2,559 |
| Fixed assets | 300 | 337 | 288 | 312 | 311 | 340 | 406 | 444 |
| Investments | — | — | — | — | 0 | 33 | 27 | 29 |
| Total assets | 3,108 | 3,303 | 3,615 | 3,782 | 3,890 | 3,782 | 4,037 | 3,602 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 200 | 231 | 204 | 312 | 264 | 140 | 129 | 50 |
| Cash from investing | -50 | -163 | -68 | -161 | -59 | -94 | -391 | -108 |
| Cash from financing | -181 | -9 | 122 | -98 | -252 | -230 | 238 | 28 |
| Net cash flow | -36 | 60 | 271 | 43 | -57 | -180 | -30 | -11 |
| Capital expenditure | -78 | -70 | -39 | -48 | -42 | -67 | -104 | -81 |
| Free cash flow | 122 | 162 | 165 | 264 | 222 | 73 | 25 | -31 |
Insider filings
24 filings between Nov 5, 2025 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
$102.2K
1 purchase by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 2
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 17
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| GRAVES JEFFREY A | $102.2K | — | Nov 5, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Veillon-Berteloot Chantal EVP & CHRO | Tax withheld | 1,455 | $24.2K |
| Jul 3, 2026 | Knight Lea Daniels EVP & Chief Financial Officer | Tax withheld | 5,226 | $94.3K |
| Jul 1, 2026 | Mosebrook Jeffrey SVP, Fin & Princ Acct Officer | Tax withheld | 937 | $16.8K |
| May 9, 2026 | BRADLEY KEITH Director | Tax withheld | 882 | $12.3K |
| May 7, 2026 | HILL BARBARA B Director | Award | 17,700 | $0 |
| May 7, 2026 | HILL BARBARA B Director | Award | 6,638 | $0 |
| Mar 11, 2026 | Knight Lea Daniels EVP & Chief Financial Officer | Tax withheld | 8,089 | $77.7K |
| Mar 11, 2026 | Veillon-Berteloot Chantal EVP & CHRO | Tax withheld | 5,420 | $52.1K |
| Mar 11, 2026 | McBreen Michael J. EVP & President, CSS | Tax withheld | 7,247 | $69.6K |
| Mar 11, 2026 | Mosebrook Jeffrey SVP, Fin & Princ Acct Officer | Tax withheld | 806 | $7.7K |
| Mar 11, 2026 | DAVIS ROBERT T. JR. EVP & President, TT | Tax withheld | 8,487 | $81.6K |
| Mar 11, 2026 | Singh Harvinder EVP & PRESIDENT, INTERNATIONAL | Option exercise | 18,922 | $0 |
| Mar 11, 2026 | Singh Harvinder EVP & PRESIDENT, INTERNATIONAL | Tax withheld | 861 | $8.3K |
| Mar 11, 2026 | Singh Harvinder EVP & PRESIDENT, INTERNATIONAL | Tax withheld | 5,190 | $49.9K |
| Mar 10, 2026 | Mosebrook Jeffrey SVP, Fin & Princ Acct Officer | Tax withheld | 341 | $3.3K |
| Mar 10, 2026 | McBreen Michael J. EVP & President, CSS | Tax withheld | 2,354 | $22.5K |
| Mar 10, 2026 | DAVIS ROBERT T. JR. EVP & President, TT | Tax withheld | 687 | $6.6K |
| Mar 10, 2026 | Singh Harvinder EVP & PRESIDENT, INTERNATIONAL | Option exercise | 1,216 | $0 |
| Mar 10, 2026 | Singh Harvinder EVP & PRESIDENT, INTERNATIONAL | Tax withheld | 601 | $5.7K |
| Jan 6, 2026 | Poul Mojdeh President & CEO | Option exercise | 542 | $0 |
| Jan 6, 2026 | Poul Mojdeh President & CEO | Tax withheld | 848 | $11.1K |
| Jan 6, 2026 | Poul Mojdeh President & CEO | Tax withheld | 542 | $7.1K |
| Jan 6, 2026 | Poul Mojdeh President & CEO | Option exercise | 848 | $0 |
| Nov 5, 2025 | GRAVES JEFFREY A Director | Purchase | 9,000 | $102.2K |
| Oct 12, 2025 | Singh Harvinder EVP & PRESIDENT, INTERNATIONAL | Tax withheld | 3,281 | $43.8K |
| Oct 12, 2025 | Singh Harvinder EVP & PRESIDENT, INTERNATIONAL | Option exercise | 11,965 | $0 |
| Sep 1, 2025 | Veillon-Berteloot Chantal EVP & CHRO | Tax withheld | 2,139 | $32.4K |
| Sep 1, 2025 | Veillon-Berteloot Chantal EVP & CHRO | Tax withheld | 1,412 | $21.4K |
| Aug 14, 2025 | ESSIG STUART Director | Other | 200,000 | $2.72M |
| Aug 14, 2025 | ESSIG STUART Director | Other | 200,000 | $2.72M |
| Jul 3, 2025 | Mosebrook Jeffrey SVP, Fin & Princ Acct Officer | Tax withheld | 3,345 | $45.1K |
| Jul 3, 2025 | Knight Lea Daniels EVP & Chief Financial Officer | Tax withheld | 2,561 | $34.5K |
| Jul 1, 2025 | Mosebrook Jeffrey SVP, Fin & Princ Acct Officer | Tax withheld | 937 | $12.4K |
| May 9, 2025 | BRADLEY KEITH Director | Award | 19,592 | $0 |
| May 9, 2025 | HILL BARBARA B Director | Award | 6,939 | $0 |
| May 9, 2025 | HILL BARBARA B Director | Award | 19,592 | $0 |
| May 9, 2025 | Clay Shaundra Director | Award | 19,592 | $0 |
| May 9, 2025 | GRAVES JEFFREY A Director | Award | 19,592 | $0 |
| May 9, 2025 | BRADLEY KEITH Director | Tax withheld | 392 | $4.8K |
| May 9, 2025 | Lo Renee Wonlai Director | Award | 19,592 | $0 |
| May 9, 2025 | ESSIG STUART Exec. Chairman of the Board | Award | 6,939 | $0 |
| May 9, 2025 | ESSIG STUART Exec. Chairman of the Board | Award | 24,898 | $0 |
| May 9, 2025 | SCHADE CHRISTIAN S Director | Award | 6,939 | $0 |
| May 9, 2025 | SCHADE CHRISTIAN S Director | Award | 19,592 | $0 |
| Mar 11, 2025 | Singh Harvinder EVP & PRESIDENT, INTERNATIONAL | Tax withheld | 647 | $15.5K |
| Mar 11, 2025 | DAVIS ROBERT T. JR. EVP & President, TT | Tax withheld | 472 | $11.3K |
| Mar 11, 2025 | DAVIS ROBERT T. JR. EVP & President, TT | Tax withheld | 907 | $21.7K |
| Mar 11, 2025 | DAVIS ROBERT T. JR. EVP & President, TT | Award | 12,425 | $0 |
| Mar 11, 2025 | Veillon-Berteloot Chantal EVP & CHRO | Tax withheld | 524 | $12.5K |
| Mar 11, 2025 | Veillon-Berteloot Chantal EVP & CHRO | Award | 7,343 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for INTEGRA LIFESCIENCES HOLDINGS CORP
Free account. Everything above stays public.
Write why you follow INTEGRA LIFESCIENCES HOLDINGS CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading